Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors

Byrne, Margaret M; Lucas, Mathew A.; Pai, Lori; Breeze, Janis L.; Parsons, Susan K.

doi:10.1111/ejh.13703

Cited by 4 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to common rashes and itchiness, RCCEP was one of the most common adverse drug reactions associated with camrelizumab. 25 , 26 In the Phase 2 clinical study of carrelizumab monotherapy for advanced HCC, 16 the incidence of RCCEP was 66.8% (145/217), respectively, and all events were grade 1 or 2, which did not lead to the interruption of treatment. It was observed that the incidence of RCCEP was significantly associated with higher objective response rate and prolongation of PFS and OS.…”

Section: Discussionmentioning

confidence: 99%

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation

Liang¹,

Liu²,

Lv³

et al. 2022

DDDT

View full text Add to dashboard Cite

Objective To validate the robust predictive values of tumor vascularity and reactive cutaneous capillary endothelial proliferation (RCCEP) in combination treatment of transarterial chemoembolization (TACE) and camrelizumab for patients with advanced hepatocellular carcinoma (HCC) and then select the potential candidates who would survive best from such treatment. Methods The clinical data of 113 patients with advanced HCC treated with TACE and camrelizumab from January 2019 to December 2021 were analyzed retrospectively. Mann Whitney U -test was used to evaluate the correlation between vascular distribution and RCCEP and tumor response; Kaplan Meier technique was used to evaluate time to progress (TTP) and overall survival (OS), and log rank test was used for comparison; multivariate Cox regression analysis was used to evaluate the related influencing factors. Results The TTP and OS of TACE combined with carrelizumab in patients with advanced HCC were 7.1 and 14.3 months. Hypervascularity and development of RCCEP were good predictors of TTP (HR 2.561, P < 0.001; HR 1.486, P = 0.032) and OS (HR 2.854, P < 0.001; HR 1.634, P = 0.011). The median TTP and OS of patients with hypervascularity and RCCEP were 10.6 and 19.3 months, which were better than those with only hypervascularity (6.8 months, P = 0.016; 11.6 months, P = 0.003) and only RCCEP (6.2 months, P = 0.039; 13.5 months, P = 0.042), as well as those with neither (3.8 months, P < 0.001; 7.4 months, P < 0.001). Conclusion Tumor hypervascularity and development of RCCEP were favorable predictive factors for the combination treatment of TACE and carrelizumab, with both of which the patients survived longest and might be the potential candidates.

show abstract

Section: Discussionmentioning

confidence: 99%

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation

Liang¹,

Liu²,

Lv³

et al. 2022

DDDT

View full text Add to dashboard Cite

show abstract

“…We focused on pre-existing neurological conditions only, so the safety of ICI use in systemic inflammatory conditions is beyond the scope of our study [25]. We also did not adjust for other factors such as smoking, which may have been relevant, given that nearly half of our patients had lung cancer and smoking had been suggested as a possible predictor for development of irAEs [26,27].…”

Section: Limitationsmentioning

confidence: 99%

Predictors for the development of neurological immune‐related adverse events of immune checkpoint inhibitors and impact on mortality

Yan,

Huang,

Swetlik

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

Background and purposeLittle is known about risk factors for developing neurological immunological adverse events (neuro‐irAEs) from immune checkpoint inhibitors (ICIs). We report the incidence, predictors for development, impact on mortality of neuro‐irAEs, and impact of ICIs on pre‐existing neurological conditions in a large clinical cohort.MethodsPatients who received ICIs between January 2011 and December 2018 were identified from a tertiary cancer center registry. Descriptive statistics were used to summarize patient, cancer, and treatment data. Odds ratios from univariable and multivariable logistic regression models were calculated to identify potential predictors for developing a neuro‐irAE. Impact of neuro‐irAEs on overall survival was estimated by Kaplan–Meier and Cox proportional hazard models.ResultsOverall frequency of neurological irAEs was 2.3%. Peripheral nervous system complications were most frequent (53.6%). Melanoma, younger age, prior chemotherapy, prior resection, CTLA‐4 ICIs exposure, and combination PD‐1 and CTLA‐4 ICIs exposure had significantly higher odds for developing a neuro‐irAE (p < 0.05) in univariate but not multivariate models. Those with a neuro‐irAE were less likely to die at 3 years compared to those without a neuro‐irAE (69% vs. 55%, p = 0.004) in univariate but not multivariate model. Flare of pre‐existing neurological condition after exposure to ICIs was present (15.4%, 2 of 13 patients) but manageable. One patient was rechallenged with ICIs without recurrent flare.ConclusionsNeuro‐irAEs are not associated with increase in overall mortality. Potential predictors for the development of neuro‐irAEs are younger age, melanoma, prior chemotherapy and resection, CTLA‐4, or combination ICIs exposure.

show abstract

Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: a retrospective cohort study

Pan

Lau

et al. 2023

British Journal of Dermatology

View full text Add to dashboard Cite

In a large, multi-institutional cohort of 672 patients with melanoma, we examined the comparative incidence and severity of immune-related adverse events among patients receiving first-line immune checkpoint inhibitors. Comparing PD-1 inhibitors, nivolumab was associated with significantly lower risk of high-grade toxicity onset compared with pembrolizumab on unadjusted logistic regression analysis. Compared with pembrolizumab, use of the CTLA-4 inhibitor ipilimumab was associated with a significant increase in risk of gastrointestinal, but not endocrine and cutaneous toxicities.

show abstract

Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors

Cited by 4 publications

References 43 publications

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation

Predictors for the development of neurological immune‐related adverse events of immune checkpoint inhibitors and impact on mortality

Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: a retrospective cohort study

Contact Info

Product

Resources

About